nivolumab,ipilimumab
bms
['niche-2']
#esmo22 amazing 95% pathologic response for niche-2 study! safety primary endpoint also met for neoadjuvant ici in locally advanced dmmr 
Cancer researcher; Director of GU Cancers @DanaFarber; Prof of Medicine @HarvardMed; ? lover; ??@PanMass
Views are mine.